A drug used for cancer therapy has shown promise in reversing kidney damage caused by systemic lupus erythematosus, according to a Yale-led study published April 8 in the journal Science Translational Medicine.

"Kidney damage affects about half of the patients with lupus, sometimes leading-edge to renal failure with a requirement for dialysis or transplantation," said Joe Craft, the Paul B. Beeson Professor of Medicine (rheumatology) and professor of immunobiology. "Finding what causes that damage is extremely important."

For more information please click here.